MarketVIEW: Japanese encephalitis vaccines

NEW YORK, Feb. 18, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

MarketVIEW: Japanese encephalitis vaccines

http://www.reportlinker.com/p0961688/MarketVIEW-Japanese-encephalitis-vaccines.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Japanese encephalitis (JE) is an enzootic mosquito-borne viral disease where humans are incidental "dead end" hosts. JE currently affects countries of SE Asia and Western Pacific where around 3 billion people are considered at risk. The disease mainly affects children (< 15yrs) in poor rural areas where it can result in 25% mortality (est 10,000 deaths/yr) or residual neuropsychiatric sequelae (30% of cases). There are no specific treatments for JE. 

This MarketVIEW product is comprised of a comprehensive MS Excel-based model(s) + Summary executive presentation which forecast the potential commercial value of Japanese Encephalitis vaccine(s) across endemic and markets to 2030. The model(s) contain value ($ m) and volume (mio doses) predictions for endemic countries in all age segments in both the public and private sector down to vaccine type. LO, BASE & HI forecast scenarios model expected demand from newly adopting countries as postulated by the PATH JE project. 

THIS PRODUCT IS A SUMMARY PRESENTATION + ONE MODEL 

Contents – Summary presentation (MS PowerPoint based)ContentsAuthors noteExecutive summaryCommercial model: key outputsJE vaccine: available market (endemic/public) ($ 000s) – all children to 2030JE vaccine: available market (endemic/public) ($ 000s) – infants to 2030JE vaccine: available market (endemic/public) ($ 000s) – 1 to 15 yrs to 2030JE vaccine: endemic segment volume analysis (mio doses/yr)JE vaccine: available market (endemic/private) ($ 000s) – 1 to 15 yrs to 2030JE vaccine: market by vaccine type 2015JE vaccines: all market segments, revenues/yr (2015)JE: disease backgroundJE: transmission cycleJE: geographic distributionJE: epidemiologyJE: genotype distributionJE: country reporting/surveillanceJE: WHO reported cases 2006 - 2010JE: disease profile of main endemic countriesRisk of JE by country, region and seasonDALYs per 100,000 persons in JE endemic countriesJE: disease trends and dynamicsJE: factors contributing to increasing transmissionJE and travelersJE: control and preventionJE control: aligned with major stakeholder objectivesPATH JE project: strategic goalsJE vaccines: policy evolutionJE vaccines: immunological aspectsImpact of JE vaccinationJE vaccination and cost effectivenessCurrently licensed JE vaccines (endemic)Country status of JE control through immunizationCountry use of JE vaccine types: SEA regionCountry use of JE vaccine types: WPR regionIndia: cases and deaths 1993 – 2009India – JE priority districtsIndia – mass vaccination campaignsIndia – mass vaccination campaigns: progress to dateTransition to new JE vaccinesAvailability of new JE vaccinesJE vaccination: country future planning – SEA regionJE vaccination: country future planning – WPR regionCommercial model: detailed assumptions per WHO region/countryJE vaccine demand forecast: countries modelledJE vaccines: modelling strategyCommercial model assumptions – SEA regionCommercial model assumptions – WPR regionPricing case studies for endemic vaccinesJE vaccine prices used in modelSource materialJE vaccines (PATH): estimated implementation 2006 – 2015Timeline of JE in Thailand 1971 – 2006Japan: immunization schedule 2011 (< 20 yrs)Japan: JEV vaccinations given 1995 – 2009 (000s)Ensebakku subcutaneous JE vaccine: History of developmentIxiaro/JESPECT – distribution structureBibliographyAbout VacZine AnalyticsDisclaimerBack pagePAGES: 81 MS PowerPoint slides, fully referenced/sourced. Available in .pdf formContents – Vaccine demand model (MS Excel-based) – endemic markets (public/private)Title sheetCHARTS – VAL (private)CHARTS – VAL (pub)CHARTS – VOL (pub)GRAND VALUE SUMMARYValue by vaccine typeValue Summary (pub <1 yrs)>Value Summary (pub 1-15 yrs)Value Summary (priv 0 - 15 yrs)Global price summaryVolume Summary (pub <1 yrs)>Volume Summary (pub 1-15 yrs)Volume Summary (priv 0 - 15 yrs)Volume SummariesSEA regionBangladesh (pub)Bangladesh (priv)Bhutan (pub)Bhutan (priv)India (pub)India (priv)Indonesia (pub)

Indonesia (priv)

Korean DPR (pub)

Timor Leste (pub)

Timor Leste (priv)

Myanmar (pub)

Myanmar (priv)

Nepal (pub)

Nepal (priv)

Pakistan (pub)

Pakistan (priv)

Sri Lanka (pub)

Sri Lanka (priv)

Thailand (pub)

Thailand (priv)

WPR region =>

Australia (pub)

Brunei (pub)

Brunei (priv)

Cambodia (pub)

Cambodia (priv)

China (pub)

Taiwan (pub)

Japan (pub)

Korea – republic (pub)

LAO PDR (pub)

LAO PDR (priv)

Malaysia (pub)

Malaysia (priv)

Papua New Guinea (pub)

Papua New Guinea (priv)

Philippines (pub)

Philippines (priv)

Russia FE (pub)

Russia FE (priv)

Vietnam (pub)

Epidemiology =>>

Endemic countries

JEV number of cases

Population databases

Birth cohorts – SEA

2 – 49 yrs SEA

Birth cohorts – WPR

2 – 49 yrs WPR

JEV – Japan data

Urban/rural split

Measles vaccine prices

Back page

WORKSHEETS: ~65

To order this report:: MarketVIEW: Japanese encephalitis vaccines

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker